- Home
- CZNC vs ATYR Comparison
CZNC vs ATYR Comparison
Compare CZNC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | ATYR |
|---|---|---|
| Founded | 1864 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 49.2M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CZNC | ATYR |
|---|---|---|
| Price | $25.80 | $0.36 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $23.50 | $3.67 |
| AVG Volume (30 Days) | 53.1K | ★ 728.9K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.87 | $0.37 |
| 52 Week High | $26.37 | $1.12 |
Technical Indicators
Market Signals| Indicator | CZNC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 25.85 |
| Support Level | $24.89 | N/A |
| Resistance Level | $26.15 | $0.59 |
| Average True Range (ATR) | 0.51 | 0.03 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 54.30 | 2.13 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).